News & Updates

Moderna publishes Phase III Covid-19 vaccine study protocol as trial enrolls more than 80% of participants


Excerpt from the Article: The company said at its R&D day that the Phase III COVE trial of mRNA-1273 had enrolled 25,296 of its planned 30,000 participants, while slightly more than 10,000 had received the first and second doses of the vaccine. One of the most closely watched Phase III Covid-19 vaccine trials is already…

Read More

Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19


Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Ufovax, LLC, (Ufovax), a vaccine biotechnology company based on the patented One-component Self-Assembling protein NanoParticle® (1c-SApNP®) vaccine design and manufacturing platform invented by Associate Professor Jiang Zhu, PhD, of Scripps Research (La Jolla, CA), announced the advancement toward Phase I clinical trials of its next-generation SARS-CoV-2 (aka “COVID-19”)…

Read More

New Coronascape tool will help unlock big-data insights for COVID-19


Excerpt from the Article: Scientists at Sanford Burnham Prebys Medical Discovery Institute today announced they have released Coronascape (, a customized version of the Metascape bioinformatics platform that removes big-data analysis hurdles for biologists. Coronascape will enable scientists to interpret the growing body of big data related to COVID-19. More than 23,000 papers about COVID-19…

Read More

Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients


Excerpt from the Press Release: LA JOLLA, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced it has completed a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) under the Coronavirus Treatment Acceleration Program (CTAP). The FDA provided…

Read More

We Had An Outstanding Time Exhibiting, Presenting and Networking at the Virtual SCDM 2020 Meeting


On September 13th we began our virtual exhibition at the SCDM 2020 meeting. What a fantastic event this year! Despite having to go virtual, the SCDM meeting organizers and AV partner were able to produce an outstanding meeting for the attendees and vendors with plenty of opportunities to network, present and of course, learn! Congratulations…

Read More

Ask Us Anything In Clinical Trials – Data Management Tools We Love and Hate To Use


Our third episode in the Ask Us Anything In Clinical Trials virtual networking series. Heather and Christopher along with their guests dive into a discussion around the Data Management tools we love and hate to use, as well as how data management is changing under the evolving conditions brought on by the pandemic. If you…

Read More

Illumina awarded NIH funding for COVID-19 test that runs 3,000 samples at once


Excerpt from the Article: San Diego gene sequencing giant Illumina has secured government funding for a COVID-19 test that can detect the novel coronavirus in thousands of samples at once, according to an announcement this week from the National Institutes of Health. The NIH awarded nine companies a total of $129 million to develop rapid,…

Read More

Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies


Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced pre-publication of a manuscript titled “Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection.”…

Read More

Argentina’s IVERCAR Ivermectin & Carrageenan Study Shows Positive Results Targeting COVID-19


Excerpt from the Article: Based in the southern end of Greater Buenos Aires, Argentina, Eurnekian Public Hospital recently sponsored a clinical trial targeting COVID-19 called the IVERCAR study. The sponsor was joined by other local hospitals acting as trial site organizations. With study results in, the Argentinian group has discovered that while in the control group,…

Read More

Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis


Excerpt from the Press Release: CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet medical need areas involving multidrug-resistant (MDR) bacterial infections and rare diseases, today announced positive topline results from ADAPT-PO, the pivotal Phase 3 clinical…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?